PDP1 and hepatocellular carcinoma: Notably, compared with the original sBBI, commercial Anti-PD-L1 or Wnt inhibitor, the designed sBBI&PDP showed stronger antitumor efficacy in an orthotopic homograft mice model of HCC and a PDX HCC model in hu-PBMC-NSG mice.